Clinical Trials Logo

Lung Diseases, Obstructive clinical trials

View clinical trials related to Lung Diseases, Obstructive.

Filter by:

NCT ID: NCT04485832 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Telehealth Could Mitigate Disease Progression Compared to Standard of Care in COPD - a Randomized Controlled Trial

Start date: April 5, 2016
Phase: N/A
Study type: Interventional

The objective of this randomised controlled trial is to test, whether telehealthcare can improve HRQOL and reduce emergency admissions and hospitalisations due to AECOPD. Different outcome parameters as described in the endpoints section will be analysed.

NCT ID: NCT04479969 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Enabling Independent Living by Expanding Access to Home-Based Pulmonary Rehabilitation

Start date: March 22, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to test an existing home-based pulmonary rehab program with the addition of video chat and a capability of a Spanish version.

NCT ID: NCT04479930 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease

Start date: December 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Objective: This study aimed to assess the effects of an integrated care plan based on an mHealth web-based platform (HappyAir) on adherence to a 1-year maintenance program applied after pulmonary rehabilitation in COPD patients. Methods: COPD patients from three hospitals were randomized to a control group or an intervention group (HappyAir group). Patients from both groups received an 8-week program of pulmonary rehabilitation and educational sessions about their illness. After completion of the process, only the HappyAir group completed an integrated care plan for 10 months, supervised by an mHealth system and therapeutic educator. The control group only underwent the scheduled check-ups. Adherence to the program was rated using a respiratory physiotherapy adherence self-report (CAP FISIO) questionnaire. Other variables analyzed were adherence to physical activity (Morisky-Green Test), quality of life (Chronic Obstructive Pulmonary Disease Assessment Test, St. George's Respiratory Questionnaire, and EuroQOL-5D), exercise capacity (6-Minute Walk Test), and lung function.

NCT ID: NCT04474717 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease in Combination With Atherosclerosis (Clinical and Biochemical Study)

Start date: November 15, 2020
Phase: N/A
Study type: Interventional

one-centered, open, non-randomized, controlled clinical trial will focus on a comprehensive study of the clinical, functional and molecular biochemical characteristics of the natural course of COPD in combination with peripheral atherosclerosis

NCT ID: NCT04473313 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Educational Follow-up in COPD Patients After Pulmonary Rehabilitation.

EDURESPI
Start date: July 16, 2020
Phase:
Study type: Observational

After pulmonary rehabilitation, the challenge is to maintain the benefits reached during the program and increase physical activity. As exercise training, education is the corner stone of pulmonary rehabilitation. Education allows to support behavioral changes in daily life. Recommendations about modalities for maintaining physical activity are still clear, however for educational follow up recommendations need to be clarified. After a pulmonary rehabilitation program, there is no defined plan for educational follow up nor location to perform education session. The aim of this study is to evaluate the proportion of patients who succeed to establish and maintain the objectives they defined during the pulmonary rehabilitation program, one year after this program.

NCT ID: NCT04459156 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

Start date: June 23, 2020
Phase: N/A
Study type: Interventional

The impact of fiber intake on short chain fatty acid (SCFA) metabolism has not been studied in subjects suffering from COPD. The purpose of this study is to compare changes in SCFA metabolism after inulin vs. placebo intake in COPD patients to healthy matched controls. This protocol is an extension of a recent study about whole-body SCFA production rates in COPD patients. The investigators hypothesize that a short-term fiber supplementation increases SCFA production in COPD patients.

NCT ID: NCT04459143 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) and Advance Directives

DIABPCO
Start date: May 16, 2019
Phase:
Study type: Observational

The aim of this study is to evaluate if the participation of COPD patients to a workshop on advance directives increases the number of patients who write them.

NCT ID: NCT04458038 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Does Chronic Obstructive Lung Disease Influence the Cognitive Function

Start date: December 7, 2020
Phase: N/A
Study type: Interventional

Studies have documented impaired cognitive function in patients with COPD. The possible reasons for this and correlation to the severity of the disease are not well described. This explorative study examines the cognitive skills of COPD patients, quantified by their ability to drive a vehicle and other cognitive test. Furthermore, we want to study the cognitive skills in COPD patients before and after they are diagnosed with and treated for obstructive sleep apnoea (OSA). The overall hypothesis is that chronic lung patients´ cognitive skills correlate with the severity of their disease. We expect that their ability to drive a vehicle drops in relation to the severity of the disease and to comorbidities.

NCT ID: NCT04457843 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

The Mobile COPD Status Test (mCST)

Start date: August 21, 2020
Phase:
Study type: Observational

Up tp now, disease activity of COPD patients in their home environment has usually been recorded by questionnaires (e.g. COPD assessment test). Digital multifactorial measurements, via the "mobile COPD Status test" app, offer a new way of displaying disease activity. However, there is no independent study that has examined whether digitally collected parameters correlate with the common used measurement instruments for COPD patients (both in cross-sectional and longitudinal course). The aim of this exploratory study is to investigate the correlation between the mobile COPD Status test (mCST App, KAIA Health) and a conventional collected clinical data set of routine measurements as well as the subjective symptoms and activity perception of COPD patients in their home environment, with and without exacerbation.

NCT ID: NCT04456673 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NOTUS
Start date: July 6, 2020
Phase: Phase 3
Study type: Interventional

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by - Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on - Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo - Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) - Pre-bronchodilator FEV1 over 52 weeks compared to placebo - Lung function assessments - Moderate and severe COPD exacerbations - To evaluate safety and tolerability - To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)